Related Experiment Video

Updated: Apr 7, 2026

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice
03:17

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice

Published on: March 29, 2024

1.1K

Fixed-dose combinations in type 2 diabetes - role of the canagliflozin metformin combination

Joshua W Fleming1, Laurie W Fleming1, Courtney S Davis1

  • 1Department of Pharmacy Practice, The University of Mississippi School of Pharmacy, Jackson, MS, USA.

Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
|July 8, 2015
PubMed

Insights

Canagliflozin-metformin offers a safe and effective treatment for type 2 diabetes mellitus (T2DM). This combination therapy significantly reduces HbA1c levels, promotes weight loss, and lowers blood pressure.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Type 2 diabetes mellitus (T2DM) management often requires combination therapies.
  • Canagliflozin, a sodium-glucose co-transporter 2 inhibitor, enhances glucose excretion.
  • Metformin is a first-line T2DM treatment.

Purpose of the Study:

  • To review the safety and efficacy of canagliflozin-metformin combination therapy for T2DM.
  • To evaluate clinical trial data on canagliflozin add-on therapy to metformin.

Main Methods:

  • Review of Phase III clinical trials involving patients with T2DM on background metformin.
  • Comparison of canagliflozin (100 mg and 300 mg) versus glimepiride and sitagliptin as add-on therapies.

Main Results:

  • Canagliflozin added to metformin reduced HbA1c by 0.73%-0.93%.
  • Canagliflozin 300 mg demonstrated superiority over sitagliptin and glimepiride.
  • Associated benefits include weight reduction (3.3-4.0 kg) and decreased systolic blood pressure (3.3-4.7 mmHg).

Conclusions:

  • The combination of canagliflozin and metformin is a safe and effective option for T2DM treatment.
  • Potential side effects include genital mycotic infections and gastrointestinal issues.
  • This combination therapy presents a promising treatment strategy for T2DM.
Keywords:
canagliflozin metforminfixed-dose combination (FDC)type 2 diabetes

More Related Videos

Fixation and Operational Method for Abdominal Massage in T2DM Mice05:57

Fixation and Operational Method for Abdominal Massage in T2DM Mice

Published on: March 7, 2025

863
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.3K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
966
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
963
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
893